Evidence map›Paper›PMID 42003865›Full record

ReviewVeterinary evidence

Immune-mediated polyarthritis in dogs: Are corticosteroids the best bet?

Hannah Walker

Abstract readReview
In one paragraph

Review in Veterinary evidence. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PICO question: In dogs with type I immune-mediated polyarthritis (IMPA), is sole treatment with other immunosuppressive agents as effective as treatment with corticosteroids at reducing clinical signs? Clinical bottom line: Category of research: Treatment. Number and type of study designs reviewed: One pragmatic open-label randomised controlled clinical trial. Strength of evidence: Weak. Outcomes reported: In the single randomised controlled clinical trial reviewed, 7/10 (70%) of dogs in both treatment groups (prednisone or cyclosporine), were reported to have shown resolution of owner-reported symptoms, clinical symptoms and improved locomotor scores and cytologic signs of disease at the end of the 90 day trial period. Of the remaining dogs, 2/3 cyclosporine treated dogs required change to prednisone, and 2/3 prednisone treated dogs required combination therapy to achieve clinical response. Conclusion: There is insufficient evidence to support the use of alternative immunosuppressive agents in place of corticosteroids for the treatment of IMPA type I. Further controlled clinical trials are needed before a change to clinical practice can be considered.

Indexed as

CANINECANIS FAMILIARISCORTICOSTEROIDSIDIOPATHICIMMUNE-MEDIATEDIMMUNE-MEDIATED POLYARTHRITISIMMUNOMODULATORSIMMUNOSUPPRESSANTSIMMUNOSUPPRESSIVEIMPAMEDICATIONPOLYARTHROPYPREDNISOLONEPREDNISONETREATMENTTYPE 1TYPE I

Identifiers

PMID42003865
PMCPMC13082272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.